The Boise, Idaho-based company discussed a renegotiated supply agreement with Inotera that should result in "significant benefit," and a new partnership announced Thursday with "The new Inotera agreement could lead to 8% to 10% higher DRAM margins from Inotera," Garg said. "Our analysis suggests this could lead to 300 to 380 basis points of higher DRAM margins in 2016 and 32 cents to 40 cents to our 2016 earnings per share estimates."